EU approves Qinlock for advanced gastrointestinal stromal tumor – Deciphera Pharma

Deciphera Pharmaceuticals announced that the European Commission (EC) has approved Qinlock (ripretinib) in the European Union (EU) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The Qinlock approval was supported by efficacy results from the primary analysis of the pivotal Phase III INVICTUS […]